Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ascendis Pharma ( (ASND) ) just unveiled an update.
Ascendis Pharma A/S on May 7, 2026 filed a Form 6-K reporting unaudited condensed consolidated interim financial statements for the quarter ended March 31, 2026, along with management’s discussion and analysis. The company posted a sharp turnaround to a net profit of €629.3 million versus a €94.6 million loss a year earlier, on revenue rising to €246.6 million, signaling significantly improved first-quarter performance and providing investors and other stakeholders with updated insight into its financial condition.
Operating profit reached €24.8 million compared with a €104.2 million operating loss in the prior-year period, while basic earnings per share swung to €10.20 from a loss of €1.58. The filing, which is incorporated by reference into multiple existing U.S. shelf and employee share plan registration statements, strengthens Ascendis Pharma’s disclosure record and may support continued access to U.S. capital as it advances its business.
The most recent analyst rating on (ASND) stock is a Buy with a $290.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Spark’s Take on ASND Stock
According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.
The score is driven primarily by improving fundamentals (rapid revenue growth, strong margins, and a move to positive operating/free cash flow) but is held back by balance-sheet risk (negative equity and high debt) and unprofitable earnings (negative P/E). Technicals are neutral-to-slightly cautious, while the latest earnings call adds support via upbeat guidance and commercial/pipeline momentum despite elevated operating expenses and near-term volatility risks.
To see Spark’s full report on ASND stock, click here.
More about Ascendis Pharma
Ascendis Pharma A/S is a Denmark-based biopharmaceutical company focused on developing and commercializing therapies, with its shares listed in the United States as a foreign private issuer. The company reports under International Financial Reporting Standards and accesses U.S. capital markets through SEC-registered equity and employee share incentive programs.
Average Trading Volume: 703,224
Technical Sentiment Signal: Buy
Current Market Cap: $14.71B
Learn more about ASND stock on TipRanks’ Stock Analysis page.